The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
Beijing will lower borrowing costs for companies, but that may not boost the economy as much as some hope.China Economyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Stocks in Asia edged higher Tuesday morning as investors await the release of minutes from the Reserve Bank of Australia's July meeting. The People's Bank of China is also set...Asia Marketsread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
Apple has spent more than $6 billion on original TV shows and movies for its forthcoming Apple TV+ service, according to a Financial Times report on Monday.Technologyread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
"These days, the consumer is addicted to convenience ... If it doesn't have a great digital presence or incredible bargains, take a pass," Jim Cramer says.Mad Money with Jim Cramerread more
* Merck makes offer of $48 per share
* Deal values Versum at $5.9 bln including debt
* Counter-offer to Versum-Entegris all-share deal
* Versum shares up 17.7 pct, Merck down 3.3 pct (Adds response from Versum)
FRANKFURT, Feb 27 (Reuters) - German drugs and lab supplies maker Merck KGaA offered $5.9 billion, including debt, for Versum Materials, in a cash deal that tops an offer from U.S. rival Entegris, as both seek to boost their electrochemicals operations.
Shares in electronic materials maker Versum soared 18 percent to $48.73 on Wednesday, while shares in Merck lost 4.6 percent and Entegris lost 2.3 percent.
Merck said it planned to buy Versum for $48 per share - or $5.2 billion excluding debt - for a premium of 16 percent to Tuesday's closing price and of 52 percent to the share price before Entegris' offer.
Entegris announced a $4 billion all-stock deal in January, saying it wanted to create a big chemical supplier to the semiconductor market at a time when the industry is under pressure.
Versum said in a statement on Wednesday that it "continues to believe in the strategic and financial rationale of the proposed merger of equals with Entegris," but its advisers will also thoroughly review the Merck proposal.
Shares in Versum, spun off from Air Products in 2016, fell 27 percent in 2018 as demand for microchips used in smartphones and other personal devices plateaued and a decade-long rally in U.S. stock markets wobbled.
Merck is building a high-tech chemicals division, called Performance Materials, that caters to the electronics industry and will complement its shrinking liquid crystals business.
The liquid crystals business used to enjoy operating income margins of 40-50 percent but is now under pressure from Chinese rivals.
Merck has said Performance Materials would return to growth in 2020, thanks to restructuring measures.
Family controlled Merck is diversified across three separate businesses, including a healthcare unit, which stems from a collaboration deal with GSK, and a life science division that makes supplies and gear for biotech labs.
To bolster its Performance Materials division, Merck in 2014 bought Britain's AZ Electronic Materials for 1.9 billion euros.
Merck said it was ready to proceed immediately to due diligence and to quickly agree a deal, adding it did not need its own shareholders to approve a transaction.
"The transaction that Versum recently disclosed significantly undervalues Versum," Merck Chief Executive Stefan Oschmann said in a letter to Versum's board of directors.
"Instead of the speculative value offered by the Entegris transaction, the all-cash proposal would deliver immediate and certain cash value to Versum stockholders and employees", he added.
The proposed deal would value Versum at 13.3 times its 2018 earnings before interest, tax, depreciation and amortisation, Oschmann said, adding he anticipated no regulatory problems.
Merck expects the deal, which it said will reap cost synergies of about 60 million euros annually, to close in the second half of 2019.
Merck is working with the bank Guggenheim and the law firm Sullivan Cromwell on the deal, which a spokesman said was fully financed with equity and debt and has not yet been discussed with Versum.
Merck has been flush with cash since the sale of its consumer health unit to Procter & Gamble for 3.4 billion euros last year.
(Reporting by Arno Schuetze and Ludwig Burger; Additional reporting by Liana B. Baker in New York; Editing by Alexandra Hudson and Elaine Hardcastle)